Next-Generation Phenotypic Screening in Early Drug Discovery for Infectious Diseases

Trends Parasitol. 2019 Jul;35(7):559-570. doi: 10.1016/j.pt.2019.05.004. Epub 2019 Jun 5.

Abstract

Cell-based phenotypic screening has proven to be valuable, notably in recapitulating relevant biological conditions, for example, the host cell/pathogen niche. However, the corresponding methodological complexity is not readily compatible with high-throughput pipelines, and fails to inform either molecular target or mechanism of action, which frustrates conventional drug-discovery roadmaps. We review the state-of-the-art and emerging technologies that suggest new strategies for harnessing value from the complexity of phenotypic screening and augmenting powerful utility for translational drug discovery. Advances in cellular, molecular, and bioinformatics technologies are converging at a cutting edge where the complexity of phenotypic screening may no longer be considered a hinderance but rather a catalyst to chemotherapeutic discovery for infectious diseases.

Keywords: black-box complexity; cell-based assay; drug screening; imaging microscopy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cells, Cultured
  • Communicable Diseases / drug therapy*
  • Computational Biology / trends*
  • Drug Discovery / methods*
  • Host-Pathogen Interactions
  • Humans
  • Phenotype